117 related articles for article (PubMed ID: 2339637)
1. Fluoride pharmacokinetics: its implications in the fluoride treatment of osteoporosis.
Ekstrand J; Spak CJ
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S53-61. PubMed ID: 2339637
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of enteric-coated sodium fluoride tablets as affected by the administration of calcium supplements at different time intervals.
Devogelaer JP; Nagant de Deuxchaisnes C; Stein F
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S75-9. PubMed ID: 2339640
[TBL] [Abstract][Full Text] [Related]
3. [Biological availability of Ossin, a sodium-fluoride dragee for osteoporosis therapy].
Becker R
Fortschr Med; 1979 Jan; 97(1):39-42. PubMed ID: 759278
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of fluoride bioavailability following the administration of sodium fluoride alone and in combination with different calcium salts.
Briançon D; D'Aranda P; Quillet P; Duplan B; Chapuy MC; Arlot M; Meunier PJ
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S71-3. PubMed ID: 2339639
[TBL] [Abstract][Full Text] [Related]
5. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
Murray TM; Ste-Marie LG
CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of terbutaline given in slow-release tablets.
Nyberg L; Kennedy BM
Eur J Respir Dis Suppl; 1984; 134():119-39. PubMed ID: 6586473
[TBL] [Abstract][Full Text] [Related]
7. Fluoride treatment of postmenopausal osteoporosis: age, renal function, and other clinical factors in the osteogenic response.
Murray TM; Harrison JE; Bayley TA; Josse RG; Sturtridge WC; Chow R; Budden F; Laurier L; Pritzker KP; Kandel R
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S27-35. PubMed ID: 2339633
[TBL] [Abstract][Full Text] [Related]
8. Relative bioavailability of fluoride from monofluorophosphate tablets after single oral administration.
Setnikar I; Maurer H
Arzneimittelforschung; 1990 Mar; 40(3):323-8. PubMed ID: 2346544
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of sodium monofluorophosphate with sodium fluoride and compatibility with calcium.
Setnikar I; Maurer H
Arzneimittelforschung; 1990 Sep; 40(9):994-9. PubMed ID: 2080951
[TBL] [Abstract][Full Text] [Related]
10. Influence of food on relative bioavailability of fluoride in man from Na2FPO3-containing tablets for the treatment of osteoporosis.
Trautner K
Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):242-9. PubMed ID: 2737790
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of osteoporosis with a delayed-action sodium fluoride preparation].
Chlud K
Z Rheumatol; 1977; 36(3-4):126-39. PubMed ID: 860605
[TBL] [Abstract][Full Text] [Related]
12. [Serum fluoride level in the NaF treatment of osteoporosis].
Fuchs C; Dorn D; Hauswaldt C; Henning HV; Köbberling J; Kubosch J; Mc Intosh C; Unger HD; Scheler F
Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():910-2. PubMed ID: 1029317
[No Abstract] [Full Text] [Related]
13. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
Delmas PD; Dupuis J; Duboeuf F; Chapuy MC; Meunier PJ
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S143-7. PubMed ID: 2339624
[TBL] [Abstract][Full Text] [Related]
14. Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis.
Pak CY; Sakhaee K; Gallagher C; Parcel C; Peterson R; Zerwekh JE; Lemke M; Britton F; Hsu MC; Adams B
J Bone Miner Res; 1986 Dec; 1(6):563-71. PubMed ID: 3503562
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.
Klotz U
Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):24-6. PubMed ID: 6799412
[TBL] [Abstract][Full Text] [Related]
17. Effect of intermittent therapy with a slow-release fluoride preparation.
Pak CY; Sakhaee K; Zerwekh JE
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S149-55. PubMed ID: 2339625
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement.
Setnikar I; Rovati LC; Schmid K; Vens-Cappell B; Barkworth MF
Arzneimittelforschung; 1998 Dec; 48(12):1172-8. PubMed ID: 9893933
[TBL] [Abstract][Full Text] [Related]
19. Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets.
Arnold P; Wermeille M; Chapuy MC; Biollaz J; Grandjean EM; Schelling JL; Meunier PJ
Bone; 1989; 10(6):401-7. PubMed ID: 2624820
[TBL] [Abstract][Full Text] [Related]
20. The use of controlled and sustained release agents in dentistry: a review of applications for the control of dental caries.
Mirth DB
Pharmacol Ther Dent; 1980; 5(3-4):59-67. PubMed ID: 6938993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
